"Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019" Published

Aug. 19, 2012 - PRLog -- GlobalData, the industry analysis specialist, has released its new report, "Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/439755_toxoplasmosis_therapeutics_pipeline_assessment.aspx
------------------------------------------------------------

Scope

The report provides information on the key drivers and challenges of the Toxoplasmosis Therapeutics market. Its scope includes -

* Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Toxoplasmosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
* Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
* Analysis of the current and future competition in the seven key countries Toxoplasmosis Therapeutics market.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Toxoplasmosis Therapeutics market.
* Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
* Develop business strategies by understanding the trends shaping and driving the global Toxoplasmosis Therapeutics market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
* Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
* What's the next big thing in the global Toxoplasmosis Therapeutics market landscape? - Identify, understand and capitalize.

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Toxoplasmosis Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Types of Toxoplasma gondii Strain
2.1.2 Life Cycle and Transmission
2.2 Epidemiology
2.2.1 Historic Epidemiology (2006-2011)
2.2.2 Forecast Epidemiology (2011-2019)
2.3 Etiology
2.3.1 Food-borne Transmission
2.3.2 Congenital Transmission
2.3.3 Zoonotic Transmission
2.3.4 Rare Instances of Transmission
2.4 Pathophysiology
2.5 Signs and Symptoms
2.6 Commonly Used Diagnostic Tests
2.6.1 Types of Diagnostic Test
2.7 Treatment and Management Options for Toxoplasmosis
2.7.1 Management of Toxoplasmosis Infection during Gestation
2.7.2 Congenital Toxoplasmosis
2.7.3 Ocular Toxoplasmosis
2.7.4 Toxoplasmosis in Immunocompetent Patients
2.8 GlobalData Pipeline Report Guidance
3 Toxoplasmosis Therapeutics - Market Characterization
3.1 Toxoplasmosis Therapeutics Market Size (2006-2011) - Global
3.2 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Global
3.3 Toxoplasmosis Therapeutics Market Size (2006-2011) - The US
3.4 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - The US
3.5 Toxoplasmosis Therapeutics Market Size (2006-2011) - France
3.6 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - France
3.7 Toxoplasmosis Therapeutics Market Size (2006-2011) - Germany
3.8 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Germany
3.9 Toxoplasmosis Therapeutics Market Size (2006-2011) - Italy
3.10 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Italy
3.11 Toxoplasmosis Therapeutics Market Size (2006-2011) - Spain
3.12 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Spain
3.13 Toxoplasmosis Therapeutics Market Size (2006-2011) - The UK
3.14 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - The UK
3.15 Toxoplasmosis Therapeutics Market Size (2006-2011) - Japan
3.16 Toxoplasmosis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market
3.17.1 Drivers for the Toxoplasmosis Therapeutics Market
3.17.2 Barriers for the Toxoplasmosis Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Toxoplasmosis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market
4.3.1 Daraprim (pyrimethamine)
4.3.2 Spiramycin
4.3.3 Sulfadiazine
4.3.4 Folinic Acid
4.4 Key Takeaway
5 Toxoplasmosis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Toxoplasmosis Therapeutics - Phase III Clinical Pipeline
5.3 Key Takeaway
6 Toxoplasmosis Therapeutics - Clinical Trial Mapping
6.1 Clinical Trials by Region and Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trial Mapping by Sponsors
6.5 Prominent Sponsors
6.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials
7 Toxoplasmosis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4397...

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.